Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Naibo, Hu"'
Autor:
Guangshuai Teng, Yuhui Zhang, Chenxiao Du, Yan Wang, Naibo Hu, Yingdi Han, Jinyu Ma, Shan Gao, Guangpeng Xiang, Zonghong Shao, Jie Bai
Publikováno v:
Blood. 140:3959-3960
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::04814cdc6b0b7d3a4919f0e0bf716f32
https://doi.org/10.1182/blood-2022-168424
https://doi.org/10.1182/blood-2022-168424
Autor:
Guangshuai Teng, Yuan Zhou, Yuhui Zhang, Naibo Hu, Tong Liu, Yingdi Han, Chao Gao, Lei Zhang, Jie Bai
Publikováno v:
Thrombosis research. 212
Post-polycythemia vera (PV) myelofibrosis (Post-PV MF) is an advanced phase of natural progression of PV. Thrombosis is a major cause of morbidity and mortality in PV; however, the characteristics of thrombosis in post-PV MF have not been characteris
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d308661da1b4e3b64083160be09f8578
https://pubmed.ncbi.nlm.nih.gov/35219930
https://pubmed.ncbi.nlm.nih.gov/35219930
Autor:
Bingyi Wang, Shiqiang Qu, Tiejun Qin, Zhijian Xiao, Naibo Hu, Zefeng Xu, Xiaoyan Du, Xiaoyun Wang, Lijuan Pan
Publikováno v:
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
BACKGROUND Hypomethylating agents (HMA) are considered the first-line therapy for high-risk myelodysplastic syndromes (MDS). However, as the efficacy and safety of rational dosing regimens are lacking, we evaluated the effectiveness and safety of red
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c49705f46d4033a5bac8007c00660104
https://pubmed.ncbi.nlm.nih.gov/33514682
https://pubmed.ncbi.nlm.nih.gov/33514682
Autor:
Jie Gao, Yudi Zhang, Zhijian Xiao, Dan Wu, Naibo Hu, Wenyu Cai, Y Zhang, Sirui Ren, Zefeng Xu, Bing Li, Huijun Huang, Gang Huang, Jinqin Liu, Lijuan Pan, Lihong Shi, Peihong Zhang, Shiqiang Qu, Jiaxi Zhou, Tiejun Qin, Changlu Xu, Meng Jiao, Robert Peter Gale
Publikováno v:
Blood Cancer Journal
Blood Cancer Journal, Vol 10, Iss 8, Pp 1-12 (2020)
Blood Cancer Journal, Vol 10, Iss 8, Pp 1-12 (2020)
The underlying mechanisms and clinical significance of ineffective erythropoiesis in myelodysplastic syndromes (MDS) remain to be fully defined. We conducted the ex vivo erythroid differentiation of megakaryocytic-erythroid progenitors (MEPs) from MD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c634a863e7964261e9f271dc34004d6
https://pubmed.ncbi.nlm.nih.gov/32801296
https://pubmed.ncbi.nlm.nih.gov/32801296
Autor:
Shiqiang Qu, Tiejun Qin, Zhijian Xiao, Bing Li, Zefeng Xu, Naibo Hu, Gang Huang, Lijuan Pan, Robert Peter Gale
Publikováno v:
Br J Haematol
We screened 47 subjects with DDX41 variants among 1529 subjects with myeloid neoplasms. The most common germline variants included Splice c.935 + 4A>T, p.T360Ifs*33, p.V152G, p.S217Ifs*4, p.R311* and p.R369*. Except for the p.R369*, no other variants
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6656804b7b8a4e56d4fdab0aaac871dd
https://europepmc.org/articles/PMC9205684/
https://europepmc.org/articles/PMC9205684/
Autor:
Zefeng Xu, Zhongxun Shi, Liwei Fang, Gang Huang, Hongli Zhang, Lijuan Pan, Bing Li, Naibo Hu, Robert Peter Gale, Zhijian Xiao, Huijun Huang, Shiqiang Qu, Tiejun Qin
Publikováno v:
Leuk Lymphoma
Myelodysplastic syndrome (MDS) is a heterogeneous clonal myeloid neoplasm of ineffective hematopoiesis, dysplasia and an increased risk of progression to acute myeloid leukemia (AML) [1]. Although ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec4dc20380ded9489c0e2596fcf7214c
https://doi.org/10.1080/10428194.2019.1607324
https://doi.org/10.1080/10428194.2019.1607324
Publikováno v:
Blood. 138:4618-4618
Thrombosis is a major cause of morbidity and mortality in polycythemia vera (PV). Post PV myelofibrosis (MF) is the advanced phase in the natural progression of PV. To explore the risk factors for thrombosis in post-PV MF, clinical characteristics, l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f95e424445a617c6217cbaaa4f5370b8
https://doi.org/10.1182/blood-2021-152115
https://doi.org/10.1182/blood-2021-152115
Publikováno v:
Blood. 138:4425-4425
The expression rate of CD38 in acute myeloid leukemia is high. It is reported that the expression of CD38 in myeloid leukemia is stable and can be used as a potential therapeutic target for leukemia. Daratumumab is a therapeutic drug targeting CD38.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::356b24527aac46c86f6261f2455a8dad
https://doi.org/10.1182/blood-2021-150193
https://doi.org/10.1182/blood-2021-150193
Autor:
Xiaofei Ai, Shiqiang Qu, Yujiao Jia, Zhijian Xiao, Yue Zhang, Wenyu Cai, Naibo Hu, Kun Ru, Tiejun Qin, Bing Li, Liwei Fang, Jinqin Liu, Jingya Wang, Zefeng Xu, Gang Huang, Hongli Zhang, Lijuan Pan
Publikováno v:
Oncotarget
// Jingya Wang 1, * , Xiaofei Ai 2, * , Tiejun Qin 3, * , Zefeng Xu 1, 3 , Yue Zhang 1, 3 , Jinqin Liu 1 , Bing Li 1, 3 , Liwei Fang 3 , Hongli Zhang 3 , Lijuan Pan 3 , Naibo Hu 3 , Shiqiang Qu 3 , Wenyu Cai 2 , Kun Ru 2 , Yujiao Jia 2 , Gang Huang 4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::768f7922952ecf494b72f13d19b52637
https://doi.org/10.18632/oncotarget.13688
https://doi.org/10.18632/oncotarget.13688
Autor:
Liwei Fang, Zhen Song, Jinqin Liu, Bing Li, Yue Zhang, Robert Peter Gale, Naibo Hu, Wenyu Cai, Zhijian Xiao, Y Y Ren, Gang Huang, Peihong Zhang, J Q Liu, Hongli Zhang, Lijuan Pan, Zefeng Xu, Shiqiang Qu, Tiejun Qin, Ruixian Xing
Publikováno v:
Oncotarget
// Bing Li 1,2,* , Jinqin Liu 2,* , Shiqiang Qu 1,* , Robert Peter Gale 3 , Zhen Song 4 , Ruixian Xing 1 , Junxia Liu 5 , Yansong Ren 5 , Zefeng Xu 1,2 , Tiejun Qin 1 , Yue Zhang 1,2 , Liwei Fang 1 , Hongli Zhang 1 , Lijuan Pan 1 , Naibo Hu 1 , Wenyu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06a586140690a4673ed0dcb2f88c140d
https://doi.org/10.18632/oncotarget.12105
https://doi.org/10.18632/oncotarget.12105